Artrya (AYA) FDA Announcement summary

Introduction and purpose

• FDA 510(k) clearance granted for Salix® Coronary Anatomy, marking a major milestone and enabling immediate US commercialization after two years of focused effort.

• Salix® offers a point-of-care approach for coronary artery disease assessment, the first major advancement in 50 years.

• Regulatory approvals now secured in the U.S., U.K., Europe, Australia, and New Zealand, enabling global commercial expansion.

Details of approval or decision

• FDA clearance enables immediate commercial access to the U.S. market, allowing sales cycle initiation with established hospital partnerships.

• The cleared product serves as a platform and predicate for upcoming products, streamlining future FDA submissions.

• Salix® Coronary Anatomy will be launched across 15 hospitals, outpatient centres, and heart and vascular centres in the US Southeast.

Impact on industry and stakeholders

• U.S. market focus due to its size (4.4 million CCTA scans/year, growing at over 6% per year) and high revenue potential, with initial partners processing 15,000 scans/year.

• Enables proactive, non-invasive coronary artery disease assessment within 10 minutes of a CCTA scan, improving workflow, reducing costs, and minimizing patient readmissions.

• Early adoption by key U.S. hospital systems and validation from major Australian providers enhance credibility.

• Commercialization efforts in the US will accelerate, leveraging existing strategic partners and expanding into new hospital systems during 2025.